Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385168 | 1.00 | MAOB (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL30384240 | 1.00 | MAOB (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL25223438 | 1.00 | MAOB (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL634191 | 1.00 | MAOB (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL25188874 | 0.92 | MAOB (0.85) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL3396591 | 0.92 | PTGS1 (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL29427953 | 0.92 | PTGS1 (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL25195740 | 0.92 | PTGS1 (1.00) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL25265209 | 0.92 | MAOB (0.85) | MAOBABCG2ACHEPTGS1PTGS2 | |
| SCHEMBL3396596 | 0.92 | PTGS1 (1.00) | MAOBABCG2ACHEPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11254700-B2 | GSK-3β inhibitors and use thereof in methods of treatment | UNIVERSITY OF HAWAII (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200331948-A1 | GSK-3ß INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT | UNIVERSITY OF HAWAII (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20080287374-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1591112-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAOB 1213/4885ABCG2 5/4885ACHE 1205/4885 |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | MAOB 1476/4885ABCG2 1523/4885ACHE 2254/4885 |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | ABCC1, BCR, BRCA1 | MAOB 3350/4885ABCG2 8/4885ACHE 4130/4885 |
| US-20200331948-A1 | GSK-3ß INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT | GSK3B, GSK3A, GSKIP | MAOB 1651/4885ABCG2 2959/4885ACHE 18/4885 |
| US-20080287374-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | ABCC1, BCR, BRCA1 | MAOB 3350/4885ABCG2 8/4885ACHE 4130/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | MAOB 3343/4885ABCG2 3800/4885ACHE 4292/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAOB 1004/4885ABCG2 1606/4885ACHE 806/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAOB 3735/4885ABCG2 3643/4885ACHE 1849/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885ABCG2 3622/4885ACHE 656/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885ABCG2 3622/4885ACHE 656/4885 |
| US-11254700-B2 | GSK-3β inhibitors and use thereof in methods of treatment | GSK3B, GSK3A, GSKIP | MAOB 1748/4885ABCG2 2621/4885ACHE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.